Anti-TNF-α was preferred as the immunomodulatory agent in most colitis cases (21/22) and treatment benefit was observed in 20/21 cases; one patient with grade 3 colitis was treated with first-line anti-TNF-α as a steroid-sparing option with toxicity resolution. The gene discussed is TNF; the disease is colitis.